| 摘要 |
PROBLEM TO BE SOLVED: To provide a sustained release dosage form that extends the local duration of action of corticosteroids for treating inflammatory diseases such as osteoarthritis or rheumatoid arthritis and pain caused by the same, while reducing systemic side effects associated with administration thereof.SOLUTION: A sustained-release formulation comprises a Class B corticosteroid, a first lactic acid-glycolic acid copolymer, and a second lactic acid-glycolic acid copolymer. The first lactic acid-glycolic acid copolymer has one or more of: (i) a molecular weight in the range of about 110 to 150 kDa; (ii) an inherent viscosity in the range of 0.6 to 1.0 dL/g; and (iii) a lactide:glycolide molar ratio of 80:20 to 60:40. The second lactic acid-glycolic acid copolymer has one or more of: (i) a molecular weight in the range of about 40 to 70 kDa; (ii) an inherent viscosity in the range of 0.2 to 0.5 dL/g; and (iii) a lactide:glycolide molar ratio of 80:20 to 60:40.SELECTED DRAWING: None |
